Cloughesy TF - Search Results

1

Perfusion and diffusion MRI signatures in histologic and genetic subtypes of WHO grade II-III diffuse gliomas.

Leu K, Ott GA, Lai A, Nghiemphu PL, Pope WB, Yong WH, Liau LM, Cloughesy TF, Ellingson BM. Leu K, et al. Among authors: cloughesy tf. J Neurooncol. 2017 Aug;134(1):177-188. doi: 10.1007/s11060-017-2506-9. Epub 2017 May 25. J Neurooncol. 2017. PMID: 28547590 Free PMC article.

2

Pharmacological blood-brain barrier modification for selective drug delivery.

Cloughesy TF, Black KL. Cloughesy TF, et al. J Neurooncol. 1995 Nov;26(2):125-32. doi: 10.1007/BF01060218. J Neurooncol. 1995. PMID: 8787854 Review.

3

Prolonged treatment with biologic agents for malignant glioma: a case study with high dose tamoxifen.

Cloughesy TF, Woods RP, Black KL, Couldwell WT, Law RE, Hinton DR. Cloughesy TF, et al. J Neurooncol. 1997 Oct;35(1):39-45. doi: 10.1023/a:1005895616377. J Neurooncol. 1997. PMID: 9266439

4

Treatment of intracranial gliomas with bone marrow-derived dendritic cells pulsed with tumor antigens.

Liau LM, Black KL, Prins RM, Sykes SN, DiPatre PL, Cloughesy TF, Becker DP, Bronstein JM. Liau LM, et al. Among authors: cloughesy tf. J Neurosurg. 1999 Jun;90(6):1115-24. doi: 10.3171/jns.1999.90.6.1115. J Neurosurg. 1999. PMID: 10350260

5

Relationships between choline magnetic resonance spectroscopy, apparent diffusion coefficient and quantitative histopathology in human glioma.

Gupta RK, Cloughesy TF, Sinha U, Garakian J, Lazareff J, Rubino G, Rubino L, Becker DP, Vinters HV, Alger JR. Gupta RK, et al. Among authors: cloughesy tf. J Neurooncol. 2000 Dec;50(3):215-26. doi: 10.1023/a:1006431120031. J Neurooncol. 2000. PMID: 11263501

6

Active matrix metalloproteinase 9 expression is associated with primary glioblastoma subtype.

Choe G, Park JK, Jouben-Steele L, Kremen TJ, Liau LM, Vinters HV, Cloughesy TF, Mischel PS. Choe G, et al. Among authors: cloughesy tf. Clin Cancer Res. 2002 Sep;8(9):2894-901. Clin Cancer Res. 2002. PMID: 12231534

7

Identification of molecular subtypes of glioblastoma by gene expression profiling.

Mischel PS, Shai R, Shi T, Horvath S, Lu KV, Choe G, Seligson D, Kremen TJ, Palotie A, Liau LM, Cloughesy TF, Nelson SF. Mischel PS, et al. Among authors: cloughesy tf. Oncogene. 2003 Apr 17;22(15):2361-73. doi: 10.1038/sj.onc.1206344. Oncogene. 2003. PMID: 12700671

8

Gene expression profiling identifies molecular subtypes of gliomas.

Shai R, Shi T, Kremen TJ, Horvath S, Liau LM, Cloughesy TF, Mischel PS, Nelson SF. Shai R, et al. Among authors: cloughesy tf. Oncogene. 2003 Jul 31;22(31):4918-23. doi: 10.1038/sj.onc.1206753. Oncogene. 2003. PMID: 12894235

9

Phase 1 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study.

Prados MD, Yung WK, Jaeckle KA, Robins HI, Mehta MP, Fine HA, Wen PY, Cloughesy TF, Chang SM, Nicholas MK, Schiff D, Greenberg HS, Junck L, Fink KL, Hess KR, Kuhn J; North American Brain Tumor Consortium study. Prados MD, et al. Among authors: cloughesy tf. Neuro Oncol. 2004 Jan;6(1):44-54. doi: 10.1215/S1152851703000292. Neuro Oncol. 2004. PMID: 14769140 Free PMC article. Clinical Trial.

10

p53 disruption profoundly alters the response of human glioblastoma cells to DNA topoisomerase I inhibition.

Wang Y, Zhu S, Cloughesy TF, Liau LM, Mischel PS. Wang Y, et al. Among authors: cloughesy tf. Oncogene. 2004 Feb 12;23(6):1283-90. doi: 10.1038/sj.onc.1207244. Oncogene. 2004. PMID: 14961077

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

360 results

Search Page